Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency.

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Abstract Text:

C H Shackleton,

Tetrahydro-19-nor-deoxycorticosterone (3 alpha, 21-dihydroxy-19-nor-5 beta-pregnan-20-one, a presumed metabolite of 19-nor-DOC was sought in the conjugated steroid fractions of urine from patients with 17 alpha-hydroxylase deficiency syndrome. The reference material was prepared by microbial reduction (Clostridium paraputrificum) of 19-nor-DOC. Urinary steroid fractions of appropriate polarity were examined by high resolution gas chromatography and gas chromatography/mass spectrometry (GC/MS) but no tetrahydro-19-nor-DOC was found. The high selectivity of the GC/MS technique ensured that the excretion of this compound could not exceed about 1% of the excretion of tetrahydroDOC. Assuming that tetrahydro-19-nor-DOC is a major metabolite of 19-nor-DOC, it can be stated that 19-nor-DOC production is not a significant feature of 17 alpha-hydroxylase deficiency. This assumption may not be valid if 19-nor-DOC is formed from DOC in the kidney and is excreted unmetabolized soon after synthesis.

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Publishing Authors By Initials

CH Shackleton,

For similar polycyclic compounds: steroids research abstracts see: polycyclic compounds: steroids research

PUBMED ID PMID:

MEDLINE DATE:

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Clinical and experimental hypertension. Part A, Th

VOLUME: 4

Page Numbers: 1529-39

Journal Abbreviation:

ISSN: 0730-0077

DAY: 12

MONTH: 02

YEAR: 1982

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8207790

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Keywords Mesh Terms:

KEYWORDS: Steroids

MESH TERMS: urine

Chemical & Substance for Abstract: Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency. Information

Substance Name: Steroid Hydroxylases

Registry Number: EC 1.14.-

Grant and Affiliation Information for Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Hypertens A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency Related Publications

• A case of eclampsia treated with hexamethonium bromide.
• Abnormal steroidogenesis in three patients with Antley-Bixler syndrome: apparent decreased activity of 17alpha-hydroxylase, 17,20-lyase and 21-hydroxylase.
• Cortisol metabolism in the Bolivian squirrel monkey (Saimiri boliviensis boliviensis).
• Evidence against significant 19-nor-deoxycorticosterone production in patients with 17 alpha-hydroxylase deficiency.
• Human Delta(4)-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism.
• Identification of plasma glucocorticoids in pallid sturgeon in response to stress.
• Morphology of physiologically characterised ventral cochlear nucleus stellate cells.
• Potential of sterol analysis by liquid chromatography-tandem mass spectrometry for the prenatal diagnosis of Smith-Lemli-Opitz syndrome.
• TEACHING IN THE REGIONAL HOSPITALS.
• The reduction of surgical haemorrhage; some observations on controlled hypotension with methonium compounds.